Tech Company Financing Transactions
Forma Therapeutics Funding Round
Forma Therapeutics closed a $100 million Series D funding round on 12/20/2019. Investors included RA Capital, Cormorant Asset Management and Samsara BioCapital.
Transaction Overview
Company Name
Announced On
12/20/2019
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series D
Investors
RA Capital (Lead Investor) (Peter Kolchinsky)
Proceeds Purpose
Financing proceeds will support the ongoing clinical development of FT-4202, FORMA's pyruvate kinase-R (PKR) activator in clinical development as a potential disease-modifying therapy for sickle cell disease (SCD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
500 Arsenal St. 100
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology and other genetically driven therapeutic areas.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Frank Lee
Chief Financial Officer
Todd Shegog
Chief Medical Officer
Patrick Kelly
Vice President
Paul Ehrlich
Vice President
Brian Lesser
Vice President
Jonathan O'Connell
VP - Bus. Development
Scott Boyle
VP - General Counsel
Jeannette Potts
VP - Human Resources
Mary Wadlinger
VP - Manufacturing
Suresh Babu
VP - R & D
Frances Duffy-Warren
Browse more venture capital transactions:
Prev: 12/20/2019: Glovo venture capital transaction
Next: 12/20/2019: Kinnate Biopharma venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs